低分子肝素在骨髓增殖性肿瘤患者血栓并发症中的应用

 骨髓增殖性肿瘤（MPN）是一组造血干／祖细胞的恶性克隆性疾病，其主要临床特点是骨髓内一系或多系髓细胞过度增殖，导致外周血中红细胞、粒细胞、血小板数目增多。动静脉血栓形成及其并发症是导致MPN死亡的重要因素。低分子肝素（LMWH）是临床上常用的较为安全有效的抗凝剂，能够改善血液高凝状态，降低血小板与白细胞、内皮细胞之间的相互作用，减轻细胞聚集，并能在高血小板血浆中发挥高效抗凝作用。为LMWH应用于MPN提供了理论基础。

Application of low molecular weight heparins in myeloproliferative neoplasms

Myeloproliferative neoplasms (MPN) are a group of diseases with malignant cloning in hematopoietic stem / progenitor cells. The main clinical feature is excessive proliferation of one or more lineage of myeloid cells, which cause increasing count of erythrocytes, granulocytes and platelets in peripheral blood.Arterio-venous thrombosis and complications are responsible for the mortality of MPN. Low molecular weight heparin (LMWH) is a kind of anticoagulant that commonly used for its safety and validity. It can improve the hyperviscosity of blood , affect platelets, and interact with leukocytes and endothelial cells, by which can reduce cells aggregation. LMWH can effectively play an active role of anticoagulant in high-platelet plasma. All of these provides a theoretical basis to its availability in MPN.